国际眼科杂志
國際眼科雜誌
국제안과잡지
International Eye Science
2015年
10期
1772-1774
,共3页
增殖性糖尿病视网膜病变%围手术期%血管内皮生长因子%雷珠单抗%康柏西普
增殖性糖尿病視網膜病變%圍手術期%血管內皮生長因子%雷珠單抗%康柏西普
증식성당뇨병시망막병변%위수술기%혈관내피생장인자%뢰주단항%강백서보
proliferative diabetic retinopathy%perioperative period%vascular endothelial growth factor%ranibizumab%conbercept
目的：对比研究玻璃体腔注射抗VEGF (血管内皮生长因子)药物治疗增殖性糖尿病视网膜病变( proliferative diabetic retinopathy,PDR)的临床疗效。<br> 方法：选取我院2010-01/2015-01收治的PDR患者84例84眼,将患者随机分为A组、B组、C组,各为28例28眼。A组直接行玻璃体切除术；B组在玻璃体切除术前于玻璃体腔注射雷珠单抗；C组在玻璃体切除术前于玻璃体腔注射康柏西普。观察三组手术时间、并发症和术后6 mo最佳矫正视力。<br> 结果：治疗后,B组、C组术中及术后并发症的发生率以及手术时间显著低于A组。三组患者术后6 mo最佳矫正视力比较,A组术前、术后视力组内比较差异均有统计学意义(P<0.05),三组在治疗后视力改善有效率方面比较,无统计学差异(P>0.05)。<br> 结论：玻璃体切除术前注射雷珠单抗和康柏西普能有效缩短手术时间,减少术中及术后并发症,并能显著提高患者最佳矫正视力。
目的：對比研究玻璃體腔註射抗VEGF (血管內皮生長因子)藥物治療增殖性糖尿病視網膜病變( proliferative diabetic retinopathy,PDR)的臨床療效。<br> 方法：選取我院2010-01/2015-01收治的PDR患者84例84眼,將患者隨機分為A組、B組、C組,各為28例28眼。A組直接行玻璃體切除術；B組在玻璃體切除術前于玻璃體腔註射雷珠單抗；C組在玻璃體切除術前于玻璃體腔註射康柏西普。觀察三組手術時間、併髮癥和術後6 mo最佳矯正視力。<br> 結果：治療後,B組、C組術中及術後併髮癥的髮生率以及手術時間顯著低于A組。三組患者術後6 mo最佳矯正視力比較,A組術前、術後視力組內比較差異均有統計學意義(P<0.05),三組在治療後視力改善有效率方麵比較,無統計學差異(P>0.05)。<br> 結論：玻璃體切除術前註射雷珠單抗和康柏西普能有效縮短手術時間,減少術中及術後併髮癥,併能顯著提高患者最佳矯正視力。
목적：대비연구파리체강주사항VEGF (혈관내피생장인자)약물치료증식성당뇨병시망막병변( proliferative diabetic retinopathy,PDR)적림상료효。<br> 방법：선취아원2010-01/2015-01수치적PDR환자84례84안,장환자수궤분위A조、B조、C조,각위28례28안。A조직접행파리체절제술；B조재파리체절제술전우파리체강주사뢰주단항；C조재파리체절제술전우파리체강주사강백서보。관찰삼조수술시간、병발증화술후6 mo최가교정시력。<br> 결과：치료후,B조、C조술중급술후병발증적발생솔이급수술시간현저저우A조。삼조환자술후6 mo최가교정시력비교,A조술전、술후시력조내비교차이균유통계학의의(P<0.05),삼조재치료후시력개선유효솔방면비교,무통계학차이(P>0.05)。<br> 결론：파리체절제술전주사뢰주단항화강백서보능유효축단수술시간,감소술중급술후병발증,병능현저제고환자최가교정시력。
AIM:To compare clinical effects of intravitreal injection of anti - vascular endothelial growth factor ( VEGF ) medicine for proliferative diabetic retinopathy( PDR) . <br> METHODS:Eighty-four patients with PDR (84 eyes) in our hospital in January 2010 to January 2015 were selected, and were randomly divided into three groups ( A, B, C, 28 eyes of 28 cases ) . The patients in group A underwent vitrectomy, those in group B received intravitreal injection of ranibizumab before vitrectomy;and those in group C got intravitreal injection of conbercept before vitrectomy. Operative time, complications, and postoperative best-corrected visual acuity at 6mo of the three groups were compared. <br> RESULTS: After treatment, the incidence of intraoperative and postoperative complications and the operation time of group B and group C were lower than those of group A. Compared best corrected visual acuity at preoperative and postoperative 6mo, and among three groups, there were no statistically significance difference (P<0. 05). There were no statistical differences compared visual acuity improvement among three groups(P>0. 05). <br> CONCLUSION: Intravitreal injection of ranibizumab and conbercept before vitrectomy can decrease the operation time and intraoperative bleeding, reduce the incidence of intraoperative and postoperative complications and improve BCVA of patients in the treatment of PDR.
